Copyright
©The Author(s) 2022.
World J Clin Cases. Jan 14, 2022; 10(2): 585-593
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.585
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.585
Table 1 Characteristics of included studies
| Title | Country | Multiple/single center | Date | Argatroban/control |
| Thrombin inhibition in the acute phase of IS using argatroban | Japan | Single center | 1995 | 7/6 |
| Effect of the argatroban in acute cerebral thrombosis | Japan | Multicenter | 1997 | 59/59 |
| Argatroban in patients with acuteischemic stroke | United States | Multicenter | 2004 | 86/47 |
| Randomized, multicenter trial of ARTSS-2 (Argatroban with Recombinant Tissue Plasminogen Activator for Acute Stroke) | United States | Multicenter | 2017 | 61/29 |
- Citation: Lv B, Guo FF, Lin JC, Jing F. Efficacy and safety of argatroban in treatment of acute ischemic stroke: A meta-analysis. World J Clin Cases 2022; 10(2): 585-593
- URL: https://www.wjgnet.com/2307-8960/full/v10/i2/585.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i2.585